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Introduction
Rheumatoid Arthritis (RA) is an autoimmune disease, multi-
functional in origin, characterised by the inflammation of the 
membrane lining joints. The disease spreads from small to large 
joints, with the greatest damage in the early phase [1]. The diagnostics 
of RA is based on clinical, radiological and immunological features. 
The most frequent serological test is the measurement of Rheumatoid 
Factor (RF). American College of Rheumatology for the classification 
of RA comprise RF as one of its criteria. The most common class 
is IgM and it is found in 60–80% of RA patients. RF is not specific 
for RA, as it is often present in healthy individuals and patients 
with other autoimmune diseases and chronic infections [2]. 30% 
of patients with SLE are RF positive (with no evidence of RA) [4]. 
Despite its low specificity, a positive RF is considered an important 
predictor of outcome in RA. Antibodies to anti-perinuclear factor 
(APF) and keratin (AKA) are considered as highly specific for RA. 
Antibodies to APF and AKA were detected by indirect immune 
fluorescence using buccal epithelium of rat oesophagus [4]. The lack 
of availability of suitable buccal cell donors has limited the use of 
APF as a routine laboratory test. The antigen of both these antibodies 
has been identified as epidermal filaggrin, an intermediate filament-
associated protein involved in the cornification of the epidermis 
[5,6].  Profilagrin, present in the keratohyaline granules of human 
buccal mucosa cells, is proteolytically cleaved into filaggrin subunits 
during cell differentiation. The protein is dephosphorylated and 
some arginine residues are converted to citrulline by the enzyme 
peptidylarginine deaminase (PAD) [7]. Auto antibodies reactive with 
linear synthetic peptides containing the unusual amino citrulline 
were present in 76% of RA sera with specificity for RA of 96% [8]. 
The antibodies in patients with RA that recognized the citrulline 
containing epitopes were predominantly of the IgG class and of 
relatively high affinity [8]. In a subsequent paper [9] it is reported 
Abstract
Aim: The aim of this study was to compare the diagnostic values 
of laboratory variables, to present quantitative evaluations of 
the anti citrullinated protein / peptide antibody (ACPA), or anti 
CCP ( anti-cyclic citrullinated peptide, anti-CCP 2) antibodies in 
second generation antibody assay diagnostic test with reference 
to sensitivity and specificity, the predictive value of the positive 
and negative test and precision of the test for ACPA antibodies, 
rheumatoid factor, C-reactive protein and DAS 28 index, in the 
early diagnosis of untreated rheumatoid arthritis.
Materials and methods: 70 participants (35 patients with 
rheumatoid arthritis not treated, 35 individuals as healthy controls) 
took part in the study. Their serum was examined using ELISA 
technology of DIA-STATTM Anti-CCP (Axis–Shield Diagnostics). 
Rheumatoid factor was examined with the test for agglutination 
(Latex RF test).
Results: We found the presence of ACPA antibodies (sensitivity of 
the test 65.71%) in 23 of the 35 examined patients with rheumatoid 
arthritis while rheumatoid factor appeared in 17 patients (sensitivity 
of the test 48.57%). Twelve patients were ACPA and rheumatoid 
factor positive, 11 were ACPA positive, but rheumatoid factor 
negative. Five patients were ACPA negative and rheumatoid factor 
positive. In 17 rheumatoid factor positive patients, ACPA antibodies 
were positive in 12 patients. Of 18 rheumatoid factor negative 
patients, 11 were ACPA positive. In the healthy control group, 1 
patient was anti-CCP 2 positive, while 2 patients were rheumatoid 
factor positive.
Conclusion: ACPA antibodies have higher sensitivity and 
specificity than rheumatoid factor in rheumatoid arthritis.
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that the ELISA test based on Cyclic Citrullinated Peptide (CCP) 
showed superior performance characteristics to one based on the 
linear version in the detection of antibodies to RA. In principle, most 
citrullinated protein/peptides are recognized by auto antibodies in 
RA sera, although with different sensitivities and specificities [10]. 
These findings suggest an important role of citrullinated antigens in 
the diagnosis of RA. Sensitivity of the anti-CCP 2 test varies between 
64% and 74% in different populations, but the specificity varies 
between 90% and 99% [11-16].
Material and Methods
The diagnosis of the RA was established on the basis of the revised 
diagnostic criteria for classification of rheumatoid arthritis, suggested 
in 1987 by the American Association for Rheumatism (ARA) [17]. 
To be diagnosed as patient with RA one must fulfil at least four out 
of seven criteria. Criteria from one to four should be present for at 
least six weeks.
70 participants were included in the study: 35 patients with newly 
diagnosed RA, not treated (28 females, 7 males) and 35 individuals as 
healthy control group (18 females, 17males), aged 18–65 years. The 
average age was 56.68 years (± 6.79) (40–65 years) in the RA group 
and 46.2 years (± 12.49) (29–65 years) in the healthy control group. 
The average duration of the disease in months was 43.97 (± 45.23), 
in the interval of 1–168 months. All the participants included in the 
study denied medical history of renal disease.
Patients with disease or condition which could directly or 
indirectly influence any change in the results were excluded from the 
study:
1. Patients with SLE, Sjögren syndrome, mixed conjunction tissue 
disease, vasculitis, autoimmune disease, age<18 years.
2. Patients treated with antibiotics and salycilate in periods under 
six months from the beginning of the study.
3. Patients who together with these medicines took medicines 
from basic line.
4. Patients with previous medical history of disease of the spleen, 
thyroid gland, liver damage, renal, hematologic, arterial hypertension, 
uric arthritis, uric infections, cardiovascular, neurologic and lung 
impairment, AIDS,.
5. Patients with diabetes mellitus, acute infections, malignant 
neoplasm, febrile conditions.
6. Patients treated with antihypertensive, diabetic and cardiac 
therapy.
7. Hypersensitive to some of the medicines or their components.
8. Patients with previous history of transfusion of blood and 
overweight.
9. Patients whose results showed that in 0 spot there was a 
glycemia, or increased level of degraded products as creatinine in 
serum and urine, urea in serum and disorder of the hematologic and 
enzymatic status.
All patients took part in this study voluntarily, so the ethical 
criteria were fulfilled.
Clinical evaluation of disease activity
The clinical evaluation was performed by the subspecialist in 
this field did. The disease activity was evaluated using DAS 28 index 
(Disease Activity Score, DAS 28) [18-21].   The index is a mathematical 
formula that allows to get a uniquely composed quantitative score, 
which comprise palpation - painful sensitive joints (max number 
28), swollen joints (max number 28), Westergren’s Erythroid 
Sedimentation Rate (ESR), and patient’s global assessment of disease 
activity (0–100 mm Visual Analogous Scale VAS) and the morning 
rigidity (minutes). DAS 28 index is ranked from 0 to 10 and a score 
under 3.2 ranks the disease as low active.
Laboratory assessment
Several laboratory variables have to be measured for a clinical 
assessment of the basic disease: Complete Blood Count (CBC) 
and differential, reactors of acute phase - RF, CRP, anti-CCP 2, 
Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), 
Alanine Aminotransferase (ALT), Creatinine Kinase (CK), Lactate 
Dehydrogenase (LDH), serum urea and creatinine.
The DIA-STATTM Anti-CCP (Axis–Shield Diagnostics) test is 
a semi quantitative/qualitative Enzyme- Linked Immuno sorbent 
Assay (ELISA) for the detection of the IgG class of auto antibodies 
specific to synthetic Cyclic Citrullinated Peptide (CCP) containing 
modified arginine residues. The test provides an additional tool in the 
diagnosis of patients with RA.
The absorbance value (optical density ratio) for the positive 
and negative control and for each sample was calculated. The 
recommended values for the test are:
Absorbance ratio Result interpretation
<0.95 Negative
>0.95 to <1.0 Borderline-recommended repeat testing
>1.0 Positive
Reference values are: under 1,26 U/ml ACPA in serum.
The test of agglutination (Latex CRP test) (BioSystems S.A. 
Reagents&Instruments Costa Brava 30, Barcelona, Spain) was used 
for determination of CRP [22-26].   Reference values are: under 6 
mg/L CRP in serum.
RF was detected with the test of agglutination (Latex RF test) 
(BioSystems S.A. Reagens& Instruments Costa Brava 30, Barcelona, 
Spain) [22, 26-30].  Reference values are: under 8 mg/L RF in serum.
For determination of ESR we used the method after Westergren, 
and normal values are:  7–8 mm for males, 11– 16 mm for females.
Statistical analysis
The Student’s t-test was used for testing the importance of 
the difference between two arithmetic means, with respect to 
proportion, which compares the middle values of certain numerical 
parameters between two groups. Wilcoxon-matched test was used 
for independent samples. Sensitivity and predictivity were defined 
for positive and negative test of examined values. P value between 
0.05 and 0.1 was taken as statistically significant. Data processing was 
done with the statistical package - Statistica 7.0
Results
Out of 35 patients with RA, RF was present in 17 patients 
(48.57%), while 23 patients (65.71%) showed presence of ACPA 
antibody, 12 patients were ACPA and RF positive (34.28%), 11 
patients (31.42%) were ACPA positive and RF negative, while 5 
patients (14.28%) were ACPA negative and RF positive. Of 18 RF 
negative patients, 11 patients (61.11%) were ACPA positive. Out of 
the total of 12 ACPA negative RA patients, 5 patients (41.66%) were 
RF positive. Of 35 examined patients with RA, sensitivity to ACPA 
was 65.71%, while RF sensitivity was 48.57%. Of 17 RF positive RA 
patients, ACPA antibody was present in 12 patients and its sensitivity 
was 70.58%.  Out of 18 RF negative RA, ACPA was present in 11 
patients and its sensitivity was 61.11%. In the healthy control group 
2 participants (5.71 %) were RF positive, while 1 (2.85%) was ACPA 
positive (Table 1).
Diagnostic performance of ACPA antibody in patients with 
RA
For ACPA antibody and RF in RA, sensitivity, specificity, 
predictive value of the positive and negative tests as well as their 
precision are shown in Table 2. ACPA antibodies showed better 
diagnostic performance than RF (sensitivity 65.71% vs. 48.57%, 
specificity 97.14% vs. 94.28%) in the detection of RA.
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Corelaion between ACPA antibody and DAS 28 index of 
activity of disease
Out of 35 patients with RA, DAS 28 > 3.2 was replaced in 28 
patients (80%). In 17 seropositive RF patients, replacement of DAS 
28 > 3.2 was found in 15 patients (88.23%). Among these 15 patients 
with DAS 28 > 3.2, 10 were ACPA positive (66.66%), and their M 
± SD (2.23 ± 0.61) was extended (1.28–3.0). In 18 seronegative RF 
patients, replacement of DAS 28 > 3.2 was found in 13 patients 
(72.22%). Among these 13 patients with DAS 28 > 3.2, 9 were ACPA 
positive (69.23%) and their M ± SD (1.92 ± 0.45) was extended (1.3–
2.6). Seropositive RF patients have higher titer of ACPA antibody 
than RF seronegative (Table 1), (1.87± 0.77 (0.92–3.0) vs. 1.56 ± 0.59 
(0.93–2.6)), and a higher DAS 28 > 3.2 index (5.04 ±1.33 (2.47–6.83) 
vs. 4.56 ± 1.76 (1.85– 7.03)). Between these two groups of ACPA 
Table 1: Anti CCP 2 antibody and RF in RA and healthy control group.
RA UNTREATED GROUP  NO 35
VALUE ( M ± SD )
RA sero-
NO 18
VALUE ( M ± SD )
RAsero+
NO 17
VALUE ( M ± SD )
HEALTHY CONTROL 
GROUP  NO 35
VALUE ( M ± SD )
Positive / Negative Positive / Negative Positive / Negative Positive / Negative
ACPA
+ > 1,26 U/ml
23/12
1,71 (± 0,69 )
( 0,92-3,0 )
11/7
1,56 ( ± 0,59 )
( 0,93-2,6 )
12/5
1,87 ( ± 0,77 )
( 0,92-3,0 )
1/34
0,95 ( ± 0,10 )
( 0,90-1,38 )
DAS 28
+ > 3,2
28/7
4,79 (± 1,56 )
( 1,85-7,03 )
13/5
4,56 ( ± 1,76 )
( 1,85-7,03 )
15/2
5,04 ( ± 1,33 )
( 2,47-6,83 )
0/35
0,00 ( ± 0,00 )
( 0,00-0,00 )
RF
+ 30 > IU/ml
17/18
346,15 ( ± 625,22 )
( 0,00-1920 )
0/18
0,00 ( ± 0,00 )
( 0,00-0,00 )
17/0
712,67 ( ± 743,72 )
( 30-1920 )
2/33
13,71 ( ± 38,73 )
( 0,00-120  )
CRP
+ 12 > mg/L
14/21
46,86 ( ± 79,19 )
( 0,00-384 )
3/15
8,66 ( ± 24,62 )
( 0,00-96 )
13/4
87,31 ( ± 96,44 )
( 0,00-384 )
4/31
5,48 ( ± 12,80 )
( 0,00-48 )
SEDIMENTATION
+ > 16
27/8
48,62 ( ± 39,81 )
( 2,0-120 )
13/5
43,94 ( ± 39,82 )
( 2,0-120 )
14/3
53,58 ( ± 40,39 )
( 5,0-120 )
4/31
9,42 ( ± 8,21 )
( 2,0-44 )
Table 2: Diagnostic performance of ACPA antibody and RF in rheumatoid arthritis.
ACPA
RA No 35
ACPA
RA- No 18
ACPA
RA+ No 17
RF
RA No 35
RF
RA-  No 18
RF
RA+  No 17
CRP
RA No 35
CRP
RA- No 18
CRP
RA+  No 17
SENSITIVITY % 65,71 61,11 70,58 48,57 0 100 66,66 16,66 76,47
SPECIFICITY % 97,14 97,14 97,14 94,28 94,28 94,28 88,57 88,57 88,57
PREDICTIVE VALUES OF 
THE POSITIVE TEST %
95,83 91,66 92,30 89,47 0 89,47 77,77 42,85 76,47
PREDICIVE VALUES OF 
THE NEGATIVE TEST %
26,08 17,03 12,82 35,29 35,29 0 40,38 36,60 11,42
PRECISION % 81,42 84,90 88,46 71,42 62,26 96,15 64,28 64,15 84,61
SER
RA No 35
SER
RA- No 18
SER
RA+  No 17
DAS 28
RA No 35
DAS 28
RA- No  18
DAS 28
RA+ No  17
SENSITIVITY % 77,14 72,22 82,35 80 72,22 88,23
SPECIFICITY % 88,57 88,57 88,57 100 100 100
PREDICTIVE VALUES OF THE POSITIVE TEST % 87,09 76,47 77,77 100 100 100
PREDICIVE VALUES OF THE NEGATIVE TEST % 20,51 13,88 8,82 16,16 12,5 5,40
PRECISION % 82,85 83,01 86,53 90 90,56 96,15
 Mean 
 Mean±SD 
 Mean±1.96*SD 
0.
0
0.
5
1.
0
1.
5
2.
0
2.
5
3.
0
3.
5
4.
0
ACPA at Healthy Control Group
ACPA in 10 RF sero positive patients with DAS 28 > 3.2
ACPA in 9 RF seronegativ patients with DAS 28 > 3.2
ACPA in 17 RF seropositive patients
ACPA in 18 RF seronegative patients
ACPA in 35 RA untreated patients
 Figure 1: Distribution of ACPA antibody.
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antibody there was no statistical relation (p=0.266). Although the 
same representation of ACPA positive patients with DAS 28 > 3.2 
was found in seropositive and seronegative patients (10 vs. 9 patients; 
66.66% vs. 69.23%), the titer of ACPA was higher in 10 RF seropositive 
patients with DAS 28 > 3.2, compared with RF seronegative patients 
with DAS 28 > 3.2 (2.23 ± 0.61 vs. 1.92 ± 0.45). Between these two 
groups there was no statistical correlation (p=0.374260) (Figure 1). 
The condition was almost equal for DAS 28 index in 9 RF seronegative, 
ACPA positive patients (5.69 ± 1.37) extent 3.31–7.03 compared with 
10 RF seropositive ACPA positive patients (5.63 ±1.01) extent 4.17–
6.83. There was no statistical correlation between DAS 28 index in RF 
seropositive and seronegative patients (p=0.379375) and between two 
groups of DAS 28 > 3.2, ACPA positive patients, but RF seropositive 
and seronegative patients (p=0.905696) (Figure 2).
A statistical correlation was found using Wilcoxon - matched 
test between ACPA in RA and healthy control group for p<0.05 (p= 
0.000002). A statistical correlation was found using Wilcoxonmatched 
test between: ACPA in RA and DAS 28, RF and CRP, SER, morning 
rigidity in the same group for p<0.05: (anti-CCP 2 vs. DAS 28 
p=0.000000; ACPA vs. RF (p=0.018345); ACPA vs. CRP p= 0.040620; 
anti-CCP 2 vs. morning rigidity (p=0.000032); ACPA vs. ESR 
(p=0.000000).
Discussion
It is reported that sensitivity of first generation anti-CCP antibody 
is approximately 68% (45–80%) and specificity is 98% (96–100%). (9) 
The report for the sensitivity of second [2] generation anti-CCP 2 
antibody is approximately 64–74%, and the specificity is 90–99% [11-
16,31,32]. The advantages of the use of anti-CCP 2 test can be seen 
in the early phase of arthritis [33]. Our conclusions for sensitivity of 
65.71% and specificity of 97.14% are similar to these studies. High 
specificity (61.11%) was found in RF negative RA patients. Mean 
sensitivity and high specificity allow ACPA antibody to be included 
as a classification criterion in RA. Although DAS 28 index, which is 
not only a laboratory variable, but also a clinical index for evaluation 
of disease, has higher sensitivity (80%) and specificity (100%), ACPA 
antibody as an isolated laboratory variable, dominated with its 
performances in the early diagnosis of undifferentiated RA. However, 
we have to pay attention to the fact that the results obtained in this 
study are lower and retreat from values given by the producer DIA-
STATTM Anti-CCP (Axis–Shield Diagnostics) (sensitivity for anti-
CCP 2 79%, specificity 100 %). Data obtained for ACPA antibody 
were higher than those from tests by other examiners [12,31,34].
It is known that the keratohyalin bodies present in human buccal 
mucosa cells contain filaggrin, a protein that is recognized by APF 
and AKAs specific antibodies present in RA patients. These antibodies 
are detectable by indirect immune fluorescence techniques, but 
they have never become part of the diagnostic repertoire of clinical 
laboratories because of difficulties in the availability and storage of 
the antigen substrates, as well as objective difficulties in interpreting 
the fluoroscopic patterns.
The recent development of synthetic peptides containing 
citrulline [8], an amino acid present in the filaggrin molecule and 
produced after its deimination, has enabled the development of an 
ELISA test. From preliminary data obtained during experimental 
trials, this test appears to have the same high specificity as APF and 
AKAs and is able to eliminate the standardization problems related 
to immunofluorescence procedures. In this study, we evaluated the 
diagnostic accuracy of this new ELISA test, which is now commercially 
available.
The sensitivity of first generation anti-CCP 2 antibodies is 
reported to be approximately 68% (45–80%) and specificity is 98% 
(96–100%) [9]. The report for sensitivity of the second [2]  generation 
anti-CCP 2 antibody is approximately 64–74%, with the specificity of 
90–99% [11-16,32]. The advantages of the use of anti-CCP 2 test might 
be seen as a possibility of an early differentiation of arthritis.(33) Our 
findings for specificity of 65.71% and specificity of 97.14% are in line 
with the frames of others studies. In addition, a high specificity is 
useful in RF negative RA patients, where it is 61.11%. Mean sensitivity 
and high specificity allow anti-CCP 2 antibody to be included as a 
classification criterion in RA. Although the DAS 28 index, which is 
not only a laboratory variable but a clinical index for the estimate of 
the disease, has higher sensitivity (80%) and specificity (100%), anti-
CCP 2 antibody, as an isolated laboratory variable, dominates with its 
performance in the early diagnosis of undifferentiated RA. However, 
we have to pay attention to the fact that the results achieved in this 
study are bellow the values given by the producer DIA-STATTM Anti-
CCP (Axis–Shield Diagnostics) (sensitivity for anti-CCP 2 79%, 
specificity 100 %). Data given for ACPA antibody are higher than 
those from previous tests by other examiners [12,31,34].
The efficacy of anti-cyclic citrullinated peptide (anti-CCP) 
antibody detection in the early diagnosis of RA is shown by 
Fernández-Suárez A et al [31], as are compared three commercially 
available Enzyme-Linked Immunoabsorbent Assay (ELISA) kits used 
for detection of such antibodies. The presence of anti-CCP antibodies 
 Mean 
 Mean±SD 
 Mean±1.96*SD 
0
1
2
3
4
5
6
7
8
9
DAS 28 > 3.2 in 10 RF seropositive, ACPA positive patients
DAS 28 > 3.2 in 9 RF seronegative, ACPA positive patients
DAS 28 > 3.2 in 17 RF seropositive patients
DAS 28 > 3.2 in 18 RF seronegative patients
DAS 28 in 35 RA untreated patients
Figure 2: Distribution of das 28 index of activity of disease.
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was analysed in the sera of 78 patients, newly diagnosed. A group 
of 50 healthy controls was also included in the study. None of them 
had previously been treated. After follow-up of 1-year, diagnosis of 
RA was confirmed in 53 patients. The ELISA kits used in the study 
were IMMUNOSCAN RA (Euro-Diagnostica AB). QUANTA Lite 
CCP IgG ELISA (INOVA Diagnostic) and DIA-STAT Anti-CCP 
(Axis-Shield Diagnostics). The sensitivity was 52,8% 58,5% and 
52,8%, respectively, and specificity 100% for all three kits. Anti-
CCP antibodies detected the presence of RA in 26% RF negative 
patients. The sum of anti-CCP antibodies of the presence of RF gave 
a sensitivity of up to 67%, with specificity ranging between 94 and 
97%. It was shown that anti-CCP antibodies had high specificity for 
the diagnosis of RA. There was no difference in terms of diagnostic 
accuracy among the three analysed ELISAs.
The presence of anti-CCP antibodies in RA suspected patients 
was investigate by Us D et al. [34] They evaluated the combination 
of these autoantibodies with some other serologic markers such as 
IgM-rheumatoid factor (IgM-RF), CRP and Antinuclear Antibodies 
(ANAs). The concentrations of RF and CRP were determined by 
quantitative immune nephelometry; titers of ANAs by indirect 
immune fluorescence and the presence of anti-CCP by a commercial 
semi quantitative micro ELISA method. 88 patients with clinically 
suspected RA were analysed, as well as 42 sex- and age-matched 
healthy blood donors. High levels of IgM-RF and CRP were found 
in 48 (54.5%) and 49 (55.7%) patients, respectively, while 47 (53.4%) 
and 25 (28.4%) patients were found positive for ANAs and anti-CCP, 
respectively. Of 48 RF positive patients, 25 were also positive for anti-
CCP and distribution rates of the markers in 25 anti-CCP positive 
patients were as follows: 100% for RF, 84% for CRP and 52% for 
ANA. The sensitivity of anti-CCP ELISA was 52.1% and specificity 
was 100%, when evaluated according to RF positivity as a main 
serologic marker of RA.
In order to explain the low sensitivity, it has to be taken in 
consideration that anti-CCP antibodies are a heterogeneous group 
of antibodies directed against different epitopes on the citrulline 
molecule, that each patient’s serum contains different subsets of 
antibodies, and that the synthetic peptide used in this assay represents 
a relatively small set of antigenic determinants that do not entirely 
encompasses the antigenic determinants present on the yet unknown 
antigenic molecule in the joint [35].
ACPA and RF in RA patients were also evaluated in terms of 
duration of disease. In patients with early arthritis the correlation 
with anti-CCP was highly significant, indicating that this assay may 
be useful even in the early phase of disease. It is important because an 
early diagnosis of RA could modify in a great deal treatment decision, 
suggesting use of more aggressive drugs that can delay progression 
of joint damage and thus substantially change the natural history of 
disease.
We can conclude that ACPA antibody assay is a very valuable test 
for diagnosis of RA. This ELISA test surpasses many of the problems 
of the APF and AKA tests, such as quantification of the results 
and standardization of the assay. Its low sensitivity does not allow 
its use as a screening test, but its high specificity, especially in the 
presence of high concentrations, allows it to become one of the most 
useful serologic tests for diagnosis of RA. When associated with RF 
determination, its specificity rises up to 100%, make it helpful in the 
differential diagnosis of RA and other rheumatic diseases. This test 
may be very influential in treatment decision strategy in patients with 
recent onset of arthritis.
Anti-CCP 2 antibodies have higher sensitivity and specificity 
than RF in RA. Anti-CCP 2 test is used in everyday clinical practice 
for the diagnosis of early undifferentiated RA.
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